Seoul National University Children's Hospital
Seoul, 110-733, South Korea
NCT Number: NCT01389882
The purpose of this study is to test the hypothesis that neurally adjusted ventilatory assist (NAVA) will allow to lower the ventilator pressure at equivalent fractions of inspiratory oxygen (FiO2) and partial pressure of CO2 of capillary blood in preterm infants in comparison with currently used standard ventilation (synchronized intermittent mandatory ventilation with pressure-support ventilation, SIMV+PSV).
Looking for future studies?
Notify MeUp to 12 week
All sexes
Interventional
Phase 2
Seoul, 110-733, South Korea
The investigators will apply crossover comparison in preterm infants who received a ventilatory support. In patient whose frequency of mandatory support is under 25, the two ventilatory modes (SIMV+PSV and NAVA) are delivered by the same ventilator (Servo-I; Maquet Critical Care AB, Solna, Sweden) and will set to maintain similar blood gas analysis results.
Determination of the type of ventilatory mode used is performed using a cluster randomization. The randomized order of ventilatory mode will be used during total 9 hours; one mode for 4 hours and another mode for 5 hours. To rule out carry-over effects, a 1-hour interval for washout was guaranteed between modes. Recordings will be obtained over a total 8 hours.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
Other names: Servo-i (Maquet Critical Care AB, Solna, Sweden)
Time frame: four hours
peak inspiratory pressure measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
mean airway pressure measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
Minute ventilation measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
Expiratory tidal volume measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
Dynamic Compliance measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
Work of breathing of patients measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
Peak electrical activity of the diaphragm
Time frame: four hours
Fraction of oxygen measured by a ventilator for 4 hours with each ventilator mode
Time frame: four hours
Capillary blood pH checked immediately after the 4-hour respiratory support with each ventilator mode
Time frame: four hours
Capillary blood pCO2 checked immediately after the 4-hour respiratory support with each ventilator mode
Time frame: four hours
Capillary blood pO2 checked immediately after the 4-hour respiratory support with each ventilator mode
Time frame: four hours
Capillary blood HCO3 checked immediately after the 4-hour respiratory support with each ventilator mode
Seoul National University Hospital
Other
Application of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants and Assessment of Its Benefits Compared to Synchronized Intermittent Mandatory Ventilation (SIMV) With Pressure Support (PS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02482012
Female Urogenital Diseases and Pregnancy Complications, Infant
Newark, Delaware, United States
View Trial DetailsNCT01477892
Female Urogenital Diseases and Pregnancy Complications, Infant, Preterm
Seoul, South Korea
View Trial DetailsNCT07237139
Chronic Lung Disease of Newborn, Female Urogenital Diseases and Pregnancy Complications
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT07736560
Ejaculation Abnormal, Female Urogenital Diseases
Istanbul, Turkey (Türkiye)
View Trial Details